Development of nanodispersion-based sildenafil metered-dose inhalers stabilized by poloxamer 188: a potential candidate for the treatment of pulmonary arterial hypertension

References

• Agrawal Y, Patel V. 2011. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2(2):81.
   PubMedGoogle Scholar
• Batrakova E, Lee S, Li S, Venne A, Alakhov V, Kabanov A. 1999. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res. 16(9):1373–1379.
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia Commission. 2014. British pharmacopoeia 2015. London: The Stationary Office.
   Google Scholar
• Crystal RG. 1991. Alveolar macrophages. In: Crystal RG, West JB, editors. The lung: scientific foundations. New York (NY): Raven Press; p. 527–538.
   Google Scholar
• Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H, Weers JG. 2000. Hollow porous particles in metered dose inhalers. Pharm Res. 17(2):168–174.
   PubMed Web of Science ®Google Scholar
• Ding AH, Nathan CF, Stuehr DJ. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 141(7):2407–2412.
   PubMed Web of Science ®Google Scholar
• Duque GA, Descoteaux A. 2014. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 5:491.
   PubMed Web of Science ®Google Scholar
• Hou S, Wu J, Li X, Shu H. 2015. Practical, regulatory and clinical considerations for development of inhalation drug products. Asian J Pharm Sci. 10(6):490–500.
   Google Scholar
• Jung SY, Seo YG, Kim GK, Woo JS, Yong CS, Choi HG. 2011. Comparison of the solubility and pharmacokinetics of sildenafil salts. Arch Pharm Res. 34(3):451–454.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Miller DW. 2003. Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev. 55(1):151–164.
   PubMed Web of Science ®Google Scholar
• Kienast K, Knorst M, Müller-Quernheim J, Ferlinz R. 1996. Modulation of IL-1 beta, IL-6, IL-8, TNF-alpha, and TGF-beta secretions by alveolar macrophages under NO2 exposure. Lung. 174(1):57–67.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. 2003. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 56(6):588–599.
   PubMed Web of Science ®Google Scholar
• McLain VC. 2008. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as use. Int J Toxicol. 27:93–128.
   PubMed Web of Science ®Google Scholar
• Miranda C, Pérez-Rodríguez Z, Hernández-Armengol R, Quiñones-García Y, Betancourt-Purón T, Cabrera-Pérez MÁ. 2018. Biowaiver or bioequivalence: ambiguity in sildenafil citrate BCS classification. AAPS Pharm Sci Tech. 19(4):1693.
   PubMed Web of Science ®Google Scholar
• Myrdal PB, Sheth P, Stein SW. 2014. Advances in metered dose inhaler technology: formulation development. AAPS Pharm Sci Tech. 15(2):434–455.
   PubMed Web of Science ®Google Scholar
• Newman SP. 2005. Principles of metered-dose inhaler design. Respir Care. 50(9):1177–1190.
   PubMedGoogle Scholar
• Pilcer G, Amighi K. 2010. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 392(1/2):1–19.
   PubMedGoogle Scholar
• Purewal TS, Grant D. 1997. Metered dose inhaler technology. Colorado: Interpharm Press.
   Google Scholar
• Ridder KB, Davies-Cutting CJ, Kellaway IW. 2005. Surfactant solubility and aggregate orientation in hydrofluoroalkanes. Int J Pharm. 295(1/2):57–65.
   PubMedGoogle Scholar
• Saleem IY, Smyth H. 2013. Tuning aerosol particle size distribution of metered dose inhalers using cosolvents and surfactants. Biomed Res Int. 2013:1.
   Google Scholar
• Sawatdee S, Hiranphan P, Laphanayos K, Srichana T. 2014. Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos. Eur J Pharm Biopharm. 86(1):90–97.
   PubMed Web of Science ®Google Scholar
• Sawatdee S, Pakawatchai C, Nitichai K, Srichana T, Phetmung H. 2015. Why sildenafil and sildenafil citrate monohydrate crystals are not stable? Saudi Pharm J. 23(5):504–514.
   PubMed Web of Science ®Google Scholar
• Sawatdee S, Phetmung H, Srichana T. 2013. Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers. Int J Pharm. 455(1/2):248–258.
   PubMedGoogle Scholar
• Sawatdee S, Srichana T. 2013. Analytical validation of sildenafil citrate inhaler preparation. Chiang Mai J Sci. 40(4):669–680.
   Web of Science ®Google Scholar
• Shaik MS, Haynes A, McSween J, Ikediobi O, Kanikkannan N, Singh M. 2002. Inhalation delivery of HFA-based metered dose anticancer agents via inhaler using methotrexate as a model drug. J Aerosol Med Clear Eff Lung. 15(3):261–270.
   PubMedGoogle Scholar
• Smyth H. 2003. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev. 55(7):807–828.
   PubMed Web of Science ®Google Scholar
• Steckel H, Müller BW. 1998. Metered-dose inhaler formulation of fluticasone 17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227. Int J Pharm. 173(1/2):25–33.
   Google Scholar
• Stein SW. 2008. Estimating the number of droplets and drug particles emitted from MDIs. AAPS Pharm Sci Tech. 9(1):112.
   PubMed Web of Science ®Google Scholar
• United States Pharmacopeial Convention. 2014. United States Pharmacopeia. USP 38-NF 33. Maryland: United States Pharmacopeial Convention.
   Google Scholar
• Van Der Vliet A, Eiserich JP, Cross CE. 2000. Nitric oxide: a pro-inflammatory mediator in lung disease? Respir Res. 1(2):67–72.
   PubMedGoogle Scholar
• Verma S, Kumar S, Gokhale R, Burgess DJ. 2011. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 406(1/2):145–152.
   PubMedGoogle Scholar
• Vervaet C, Byron PR. 1999. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm. 186(1):13–30.
   PubMedGoogle Scholar
• Voorhees PW. 1985. The theory of Ostwald ripening. J Stat Phys. 38(1/2):231–252.
   Web of Science ®Google Scholar
• Wu L, Zhang J, Watanabe W. 2011. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 63(6):456–469.
   PubMed Web of Science ®Google Scholar